Merck has secured another promising expansion opportunity for its leading oncology drug KEYTRUDA, receiving priority review designation from the FDA for two bladder cancer treatment applications.
Merck revealed on Monday that the FDA has accepted two supplemental Biologics License Applications covering KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). Each application evaluates these agents when combined with Padcev (enfortumab vedotin-ejfv) for treating muscle-invasive bladder cancer in patients suitable for cisplatin-based chemotherapy.
The regulatory agency established a Prescription Drug User Fee Act target decision date of August 17, 2026.
Priority review designation applies to treatments that could deliver significant therapeutic advances for serious medical conditions. This classification generally compresses the evaluation period to approximately six months, versus the conventional ten-month timeline.
Both applications draw support from findings in the Phase 3 KEYNOTE-B15 clinical trial. This research demonstrated superior survival outcomes among muscle-invasive bladder cancer patients receiving the KEYTRUDA and Padcev combination therapy.
Merck withheld detailed trial statistics from Monday’s statement, though the FDA’s priority review determination suggests the agency recognizes potentially transformative clinical evidence.
Presently, the authorized indication for KEYTRUDA combined with Padcev encompasses adult patients with locally advanced or metastatic urothelial cancer across the United States, European Union, Japan, and additional markets.
These pending applications would broaden usage into an earlier disease stage — specifically the muscle-invasive context — where therapeutic goals frequently center on achieving cure.
Following approval, the KEYTRUDA and KEYTRUDA QLEX combinations with Padcev would represent the inaugural perioperative therapies for MIBC patients without regard to cisplatin eligibility status.
This represents a significant advancement. The current approved indication covers MIBC patients unable to receive cisplatin-based chemotherapy. These new submissions would encompass cisplatin-eligible patients as well — substantially expanding the addressable patient population.
Perioperative treatment encompasses therapy administered surrounding surgical intervention, which constitutes standard care for muscle-invasive bladder cancer. Securing this treatment setting with priority review status positions Merck advantageously from a regulatory standpoint approaching the August deadline.
KEYTRUDA QLEX represents a subcutaneous formulation of pembrolizumab, enabling administration through injection beneath the skin instead of intravenous infusion. This delivery method could provide practical advantages compared to traditional IV administration.
Merck’s shares advanced 3.13% on Monday following the announcement. The August 17 target deadline now represents a critical milestone for investors monitoring the company’s oncology development portfolio.
The post Merck (MRK) Shares Climb 3% Following FDA Priority Review for KEYTRUDA Bladder Cancer Treatment appeared first on Blockonomi.
